期刊文献+

芳酰基类蛋白酪氨酸激酶抑制剂的合成及其活性研究

Synthesis and protein tyrosine kinases inhibitory activity of aroyl derivatives
下载PDF
导出
摘要 目的以Ex-Rad为先导化合物,设计并合成具有蛋白酪氨酸激酶(PTK)抑制活性的芳酰基类化合物。方法分别以1-[(4-氟苯基)氨基甲酰基]环丙烷羧酸、1-苯基咪唑烷-2-酮为原料合成中间体3a^3d,将中间体与羧酸通过酰氯法合成目标化合物T1~T7。用酶联免疫吸附法(ELISA)测定PTK抑制活性,计算抑制率,筛选出具有抑制PTK活性的化合物。结果合成芳酰基类新化合物7个,结构经~1H NMR确证。活性初筛发现化合物T_2、T_6的抑制活性强于先导化合物。结论合成方法简单,原料价廉易得。ELISA法测定结果表明T_2、T_6的PTK的抑制活性较强。 Objective Using Ex-Rad as a lead compound to design and synthesize aroyl derivatives with protein tyrosine kinases(PTK)inhibitiory activity. Methods 1-[(4-Fluorophenyl)amioncarbonyl]cyclopropanecarboxylic acid,and 2-oxo-1-phenylimidazolidine were used as raw materials to synthesize intermediates 3a-3d,respectively. The target compounds T_1-T_7 were synthesized by chloroformylation reaction with 3a-3d. Enzyme-linked immunosorbent assay(ELISA)was used and inhibitory rate was calculated to screen out the compounds with PTK inhibitory activity. Results Seven new compounds containing aroyl groups were synthesized and their structures were confirmed by^1 H NMR. The evaluation of the seven compounds demonstrated that PTK inhibitory activity of T_2 and T_6were stronger than that of the lead compound. Conclusion The synthetic method is simple,and the materials are cheap and readily available. T_2 and T_6show strong PTK inhibitory activity by ELISA.
出处 《国际药学研究杂志》 CAS CSCD 北大核心 2016年第3期471-475,共5页 Journal of International Pharmaceutical Research
基金 国家自然科学基金资助项目(81273431 81072531 21102176)
关键词 设计合成 芳酰基 蛋白酪氨酸激酶抑制剂 design and synthesis aroyl group protein tyrosine kinases inhibitor
  • 相关文献

参考文献16

二级参考文献106

  • 1许治良,高虹,欧阳克清,郑旭煦,蔡昭皙,胡应和.G-蛋白偶联受体的功能测定和高通量药物筛选[J].中国药理学通报,2003,19(12):1330-1365. 被引量:12
  • 2Jimeno A,Hidalgo M.Multitargeted therapy:can promiscuity be praised in an era of political correctness?[J].Crit Rev Oncol Hematol,2006,59(2):150-158.
  • 3De Jonge MJ,Verweij J.Multiple targeted tyrosine kinase inhibition in the clinic:all for one or one for all?[J].Eur J Cancer,2006,42(10):1351-1356.
  • 4Keith CT,Borisy AA,Stockwell BR.Multicomponent therapeutics for networked systems[J].Nat Rev Drug Discov,2005,4(1):71-78.
  • 5Arora A,Scholar EM.Role of tyrosine kinase inhibitors in cancer therapy[J].J Pharmacol Exp Ther,2005,315(3):971-979.
  • 6Blume-Jensen P,Hunter T.Oncogenic kinase signalling[J].Nature,2001,411(6835):355-365.
  • 7Konecny GE,Pegram MD,Venkatesan N,et al.Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells[J].Cancer Res,2006,66(3):1630-1639.
  • 8Burris HA,Hurwitz HI,Dees EC,et al.Phase Ⅰ safety,pharmacokinetics,and clinical activity study of lapatinib (GW572016),a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases,in heavily pretreated patients with metastatic carcinomas[J].J Clin Oncol,2005,23(23):5305-5313.
  • 9Hanrahan EO,Heymach JV.Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer[J].Clin Cancer Res,2007,13(15):4617-4622.
  • 10Arnold AM,Seymour L,Smylie M,et al.Phase Ⅱ study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy:National Cancer Institute of Canada Clinical Trials Group Study BR.20[J].J Clin Oncol,2007,25(27):4278-4284.

共引文献75

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部